These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1114 related articles for article (PubMed ID: 1643424)

  • 61. Immunotherapy of metastases with lymphocytes treated with exogenous RNA in mice bearing B16 melanoma.
    Watanabe MA; Almeida DO; Serrano SV; Sales VS; Soares FA; de Lucca FL
    Cell Mol Biol (Noisy-le-grand); 1997 May; 43(3):393-8. PubMed ID: 9193794
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2.
    Mendiratta SK; Thai G; Eslahi NK; Thull NM; Matar M; Bronte V; Pericle F
    Cancer Res; 2001 Feb; 61(3):859-63. PubMed ID: 11221870
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immunologic enhancement of B16 melanoma growth.
    Ershler WB; Tuck D; Moore AL; Klopp RG; Kramer KE
    Cancer; 1988 May; 61(9):1792-7. PubMed ID: 3258540
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Resistance to melanoma in mice immunized with semiallogeneic fibroblasts transfected with DNA from mouse melanoma cells.
    de Zoeten EF; Carr-Brendel V; Cohen EP
    J Immunol; 1998 Mar; 160(6):2915-22. PubMed ID: 9510195
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice.
    Hirahara N; Nio Y; Sasaki S; Minari Y; Takamura M; Iguchi C; Dong M; Yamasawa K; Tamura K
    Oncology; 2001; 61(1):79-89. PubMed ID: 11474253
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Boerhaavia diffusa stimulates cell-mediated immune response by upregulating IL-2 and downregulating the pro-inflammatory cytokines and GM-CSF in B16F-10 metastatic melanoma bearing mice.
    Manu KA; Kuttan G
    J Exp Ther Oncol; 2008; 7(1):17-29. PubMed ID: 18472639
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Murine melanoma-specific tumor rejection activity elicited by a purified, melanoma-associated antigen.
    Hearing VJ; Gersten DM; Montague PM; Vieira WD; Galetto G; Law LW
    J Immunol; 1986 Jul; 137(1):379-84. PubMed ID: 3711669
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Immunological analysis of melanoma-specific antigen].
    Wakabayashi S; Okamoto S
    Nihon Hifuka Gakkai Zasshi; 1985 Oct; 95(11):1145-51. PubMed ID: 3879298
    [No Abstract]   [Full Text] [Related]  

  • 69. [Immunogenicity of 2 murine B16 melanoma variants with high metastatic potential].
    Hosni M; Santini R; Deschaux P; Pacheco H
    C R Seances Soc Biol Fil; 1990; 184(1):47-54. PubMed ID: 2150781
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice.
    Mahnke K; Qian Y; Fondel S; Brueck J; Becker C; Enk AH
    Cancer Res; 2005 Aug; 65(15):7007-12. PubMed ID: 16061687
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
    Gold JS; Ferrone CR; Guevara-Patiño JA; Hawkins WG; Dyall R; Engelhorn ME; Wolchok JD; Lewis JJ; Houghton AN
    J Immunol; 2003 May; 170(10):5188-94. PubMed ID: 12734366
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Induced Pluripotent Stem Cell-conditioned Medium Suppressed Melanoma Tumorigenicity Through the Enhancement of Natural-Killer Cellular Immunity.
    Hsieh CT; Luo YH; Chien CS; Wu CH; Tseng PC; Chiou SH; Lee YC; Whang-Peng J; Chen YM
    J Immunother; 2016 May; 39(4):153-9. PubMed ID: 27023059
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
    Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
    Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.
    Okada H; Attanucci J; Giezeman-Smits KM; Brissette-Storkus C; Fellows WK; Gambotto A; Pollack LF; Pogue-Geile K; Lotze MT; Bozik ME; Chambers WH
    Cancer Res; 2001 Mar; 61(6):2625-31. PubMed ID: 11289140
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy.
    Stagg J; Lejeune L; Paquin A; Galipeau J
    Hum Gene Ther; 2004 Jun; 15(6):597-608. PubMed ID: 15212718
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
    Li T; Harada M; Tamada K; Abe K; Nomoto K
    Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.
    Kurosawa S; Harada M; Matsuzaki G; Shinomiya Y; Terao H; Kobayashi N; Nomoto K
    Immunology; 1995 Jun; 85(2):338-46. PubMed ID: 7642226
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy.
    Shrayer DP; Bogaars H; Hearing VJ; Wanebo HJ
    J Exp Ther Oncol; 1996 Mar; 1(2):126-33. PubMed ID: 9414396
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Differentiation and the tumorigenic and metastatic phenotype of murine melanoma cells.
    Kameyama K; Vieira WD; Tsukamoto K; Law LW; Hearing VJ
    Int J Cancer; 1990 Jun; 45(6):1151-8. PubMed ID: 2161802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.